


Attorney's Docket No. 9022-30



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: S. Gupta et al. Confirmation No.: 6114
Serial No.: 10/010,914 Group Art Unit: 1616
Filed: December 5, 2001 Examiner: F. Choi
For: ***PHARMACEUTICAL COMPOSITIONS OF FENRETINIDE HAVING
INCREASED BIOAVAILABILITY AND METHODS OF USING THE SAME***

November 29, 2004

Mail Stop Amendment
Commissioner for Patents
Post Office Box 1450
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)
FOR APPLICATION FILED AFTER JUNE 30, 2003**

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the waiver by the U.S. Patent and Trademark Office of requirements under 37 C.F.R. § 1.98(a)(2)(i) for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC § 371 after June 30, 2003. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(c), before final Office Action or Allowance, whichever is earlier.

In accordance with the requirements of 37 C.F.R. § 1.97(c)(2), the \$180.00 fee specified in 37 C.F.R. § 1.17(p) is enclosed. This amount is believed to be

12/02/2004 WABDELRL 00000078 10010914


02 FC:1806

180.00 OP

In re: Gupta et al.
Serial No.: 10/010,914
Filed: December 5, 2001
Page 2

correct. However, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,




Kenneth D. Sibley
Registration No. 31,665

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10


Express Mail Label No.: **EV 473662955 US**
Date of Deposit: **11/29/04**

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Evelyn Casey

Substitute form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/010,914
		Filing Date	December 5, 2001
		First Named Inventor	Shanker Gupta
		Group Art Unit	1641
		Examiner Name	Choi
Sheet 1 of		Attorney Docket Number	9022.30



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	Number	Kind Code (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	Grit et al., "Chemical Stability of Liposomes: Implications for their Physical Stability," <i>Chemistry and Physics of Lipids</i> , 64 , pp 3-18 (1993)	
	2.	Young et al., "Phospholipid-Stabilized Nanoparticles of Cyclosporine A by Rapid Expansion from Supercritical to Aqueous Solution," <i>AAPS PharmSciTech</i> 2003; 5 (1) Article 11 (http://www.aapspharmscitech.org).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.